Boule Diagnostics resolves on a fully secured preferential rights issue of approximately SEK 150 million
Long term growth in sales above 10 percent per year
An operating margin (EBIT-margin) above 15 percent
Net debt (interest bearing debts minus cash and cash equivalents) no greater than three times operating profit (EBIT) on an annualized basis.
The annual dividend should correspond to 25-50 percent of profit for the period, after due consideration of company liquidity.
Boule Diagnostics’ share were listed on NASDAQ Stockholm, on June 23, 2011. The number of shareholders is as of December 31, 2022 3,110.
Here you will find Boules financial reports. Last published report is the Interim report Q4
In Boule´s financial calendar you can see dates for our reports.
Interim report Q1, 3 May 2023
Annual general meeting 4 May 2023
Interim report Q2, 24 July 2023
Boule is a Swedish public company. Boule applies the Swedish Companies Act and its rules and regulations. The company also follows the regulations that apply to listed companies with the NASDAQ OMX Nordic Exchange as well as the Swedish Code of Corporate Governance (the ”Code”). The Code applies to all Swedish listed companies whose shares are listed with a regulated market in Sweden. The code is based on principles of compliance. The company does not expect to deviate from the Code.
Boule as an investment
Boule operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through more than 200 distributors and partners in more than 100 countries, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011
Operating cash flow